Replies to post #767571 on NorthWest Biotherapeutics Inc (NWBO)

[survivor1x]

The patients that would normally exhibit the worse prognosis performed the best.

If a subgroup of GBM4 patients (mesenchymal) that normally die first , now become the longest lived subgroup after DCVAX, there is more than just a signal here. Crossover is definitely muddied even more here because many GBM4 patients likely transitioned to a more mesenchymal signature after recurrence. (
( https://pmc.ncbi.nlm.nih.gov/articles/PMC4774466/ )

It makes sense, - more aggressive cancer's are more easily spotted by an immune treatment. Many cancers become more aggressive upon recurrence - IMO a survival mechanism after being radiated, poisoned and starved of O2. Keytruda also saw that its treatment performed better with the patients that had higher genetic mutations like smokers. - So there is precedence here.

Worse Prognosis https://academic.oup.com/brain/article/142/4/847/5420896
Best Response https://pmc.ncbi.nlm.nih.gov/articles/PMC3071163/

[DrHigh]

Breaking my own rule here by responding..... you can go on and on about not believing in the science but you are wasting your time. One can believe in Linda Liau and SIR Keyoumars Ashkan who say this treatment is effective and desperately needed for their patients along with a long list of other clinicians. OR an internet shill who wastes hours upon hours of their time on a stock they have no financial interest in. HMMMMMM this is a tough one